A Study to Evaluate the Safety and Effectiveness of Antithrombotics to Treat Hospitalized COVID-19 Patients

Overview

About this study

This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

≥ 18 years of age.
Hospitalized for COVID-19*.
Enrolled within 72 hours of hospital admittance or 72 hours of positive COVID test.
Expected to require hospitalization for > 72 hours.

* It is strongly recommended to confirm SARSCoV2 with a positive microbiological test prior to randomization. At centers where there is delay in confirming the diagnosis, a sufficiently high clinical suspicion is sufficient to proceed with randomization as long as confirmation is expected
within 24 hours.

Exclusion Criteria:

Imminent death.
Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization.
Pregnancy.

Eligibility last updated 10/18/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Leslie Padrnos, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Leslie Padrnos, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials